• The Journal of Korean Physical Therapy
• /
• 제10권2호
• /
• pp.173-181
• /
• 1998

물리치료(physic treatment)의 주목적은 통통정복에 있다고 할 수 있으며 이를 위해 지금까지 수많은 치료적 방법들이 개발되어왔고 지금 이 순간에도 많은 연구자들이 완전한 동통치료의 방법을 찾기 위해 노력중이다. 이중 일부 연구는 기존의 치료방법과 최근위 방법들을 조화시켜 새로운 방법을 만들고자 하는 시도가 이루어지고 있으며 최근에 미국과 일본을 중심으로 서구에서 진행되고 있는 고대 중국의 침점을 이용한 치료방법의 연구나 1950년대 Nogier가 연구발전시킨 외이치료(auricular therapy)는 그 이론적 배경을 중국의 고전의학에 두고 있는 좋은 예라 하겠다. 1970년대 초, 미국과 중국의 문호개방을 통해 음으로 서구에 소개되었던 침마취의 탁월한 진통효과는 과학적사고를 중요시하는 대부분의 서구 연구자들의 반대에 부딪혀 일시적인 인기에 그쳤으나 1960년대에 Melzack과 Wall에 의해 발표되었던 관문조절설이나 1970년대 Herpes에 의해 발견되었던 엔케팔린(enkephalin)과 같은 내재성 아편물질들은 침술(acupuncture)을 "이해할 수 있는 학문"으로 점차 자리잡게 하였고 새로운 진통방법을 연구하고자 하는 욕구와 비침해적이고 비중독적인 치료방법이 환영을 받는 시대적 조류에 힘입어 외이치료와 같은 침점을 이용한 치료가 서구를 중심으로 다시 각광받고 있으며 연구활동 또한 활발히 진행되고 있다. 본문에서도 살펴보았듯이 이침점을 이용한 올바른 방법의 치료는 동통부위의 진단과 기존의 전기치료나 동통치료방법으로는 쉽게 적응하기 힘든 부위에까지 치료를 가능케 함으로써 물리치료의 대상영역을 더욱 확대시킬 수 있을 것이라 생각한다.

• 한국식품영양과학회지
• /
• 제36권2호
• /
• pp.246-249
• /
• 2007

Phenylalnine은 enkephalin, endorphine의 분해를 촉진하는 carboxypeptidase, aminopeptidase의 작용을 억제하는 필수아미노산으로 식욕억제, 정서 안정, 통증, 기분조절 관련 아미노산이다. 자연계의 L-phenylalanine과 비교하여 물리화학적 당량반응으로 구조가 보다 안정한 DL-phenylalnine(DLPA)을 소재로 가공적성을 조사하였다. DLPA는 $60^{\circ}C$ 이상의 온도와 농도변화에서 용해 시 98%T 이상의 값을 나타내어 가공 적합성을 보였고, 다양한 pH 범위에서도 99%T 이상의 값을 보여 용해 안정성을 확인하였다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제5권3호
• /
• pp.213-221
• /
• 2001

The amygdala is known as a site for inducing analgesia, but its action on the trigeminal nucleus has not been known well. Little information is available on the effect of dynorphin on NMDA receptor-mediated electrophysiological events in the trigeminal nucleus. The purpose of this study was to investigate the changes in the single neuron spikes at the trigeminal nucleus caused by the amygdala and the action of dynorphin on the trigeminal nucleus. In the present study, extracellular single unit recordings were made in the dorsal horn of the medulla (trigeminal nucleus caudalis) and the effects of microiontophoretically applied compounds were examined. When [D-Ala2, N-Me-Phe4, Glys5-ol]enkephalin (DAMGO, 10-25 mM), a ${\mu}-opioid$ receptor agonist, was infused into the amygdala, the number of NMDA-evoked spikes at the trigeminal nucleus decreased. However, the application of naloxone into the trigeminal nucleus while DAMGO being infused into the amygdala increased the number of spikes. Low dose (1 mM) of dynorphin in the trigeminal nucleus produced a significant decrease in NMDA-evoked spikes of the trigeminal nucleus but the NMDA-evoked responses were facilitated by a high dose (5 mM) of dynorphin. After the ${\kappa}$ receptors were blocked with naloxone, dynorphin induced hyperalgesia. After the NMDA receptors were blocked with AP5, dynorphin induced analgesia. In conclusion, dynorphin A exerted dose-dependent dual effects (increased & decreased spike activity) on NMDA-evoked spikes in the trigeminal nucleus. The inhibitory effect of the dynorphin at a low concentration was due to the activation of ${\kappa}$ receptors and the excitatory effect at a high concentration was due to activation of NMDA receptors in the trigeminal neurons.

• The Korean Journal of Physiology and Pharmacology
• /
• 제20권5호
• /
• pp.525-531
• /
• 2016

The analgesic mechanism of opioids is known to decrease the excitability of substantia gelatinosa (SG) neurons receiving the synaptic inputs from primary nociceptive afferent fiber by increasing inwardly rectifying $K^+$ current. In this study, we examined whether a ${\mu}$-opioid agonist, [D-Ala2,N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO), affects the two-pore domain $K^+$ channel (K2P) current in rat SG neurons using a slice whole-cell patch clamp technique. Also we confirmed which subtypes of K2P channels were associated with DAMGO-induced currents, measuring the expression of K2P channel in whole spinal cord and SG region. DAMGO caused a robust hyperpolarization and outward current in the SG neurons, which developed almost instantaneously and did not show any time-dependent inactivation. Half of the SG neurons exhibited a linear I~V relationship of the DAMGO-induced current, whereas rest of the neurons displayed inward rectification. In SG neurons with a linear I~V relationship of DAMGO-induced current, the reversal potential was close to the $K^+$ equilibrium potentials. The mRNA expression of TWIK (tandem of pore domains in a weak inwardly rectifying $K^+$ channel) related acid-sensitive $K^+$ channel (TASK) 1 and 3 was found in the SG region and a low pH (6.4) significantly blocked the DAMGO-induced $K^+$ current. Taken together, the DAMGO-induced hyperpolarization at resting membrane potential and subsequent decrease in excitability of SG neurons can be carried by the two-pore domain $K^+$ channel (TASK1 and 3) in addition to inwardly rectifying $K^+$ channel.

• Molecules and Cells
• /
• 제45권8호
• /
• pp.537-549
• /
• 2022

Preproenkephalin (PPE) is a precursor molecule for multiple endogenous opioid peptides Leu-enkephalin (ENK) and Met-ENK, which are involved in a wide variety of modulatory functions in the nervous system. Despite the functional importance of ENK in the brain, the effect of brain-derived factor(s) on PPE expression is unknown. We report the dual effect of neural epidermal growth factor (EGF)-like-like 2 (NELL2) on PPE gene expression. In cultured NIH3T3 cells, transfection of NELL2 expression vectors induced an inhibition of PPE transcription intracellularly, in parallel with downregulation of protein kinase C signaling pathways and extracellular signal-regulated kinase. Interestingly, these phenomena were reversed when synthetic NELL2 was administered extracellularly. The in vivo disruption of NELL2 synthesis resulted in an increase in PPE mRNA level in the rat brain, suggesting that the inhibitory action of intracellular NELL2 predominates the activation effect of extracellular NELL2 on PPE gene expression in the brain. Biochemical and molecular studies with mutant NELL2 structures further demonstrated the critical role of EGF-like repeat domains in NELL2 for regulation of PPE transcription. These are the first results to reveal the spatio-specific role of NELL2 in the homeostatic regulation of PPE gene expression.

• 대한약리학회지
• /
• 제30권3호
• /
• pp.299-311
• /
• 1994

Pentazocine은 opioid 수용체에 대한 흥분작용과 길항작용을 겸유한 opioid계 약물로 알려져 있다. 본 연구에서 흰쥐 적출 관류부신으로 부터 pentazocine의 catecholamine(CA) 분비작용을 관찰하여 그 기전을 규명하고 또한 다른 opioid의 작용과 비교하여 얻어진 결과는 다음과 같다. Pentazocine$(30{\sim}300\;ug)$을 부신정맥내에 주사하였을때 현저한 용량의 존성의 CA 분비작용을 나타내었다. Pentazocine의 이러한 CA 분비작용은 chlorisondamine $(10^{-6}\;M)$, naloxone $(1.22{\times}10^{-7}\;M)$, morphine $(1.73{\times}10^{-5}\;M)$, enkephalin $(9.68{\times}10^{-6}\;M)$, nicardipine $(10^{-6}\;M)$ 및 TMB-8$(10^{-5}\;M)$등의 전처치로 뚜렷이 억제되었으나 pirenzepine (2과$10^{-6}\;M)$의 전처치에 의해서는 영향을 받지 않았다. $Ca^{++}$-free Krebs 용액으로 30분간 관류한 후에 pentazocine의 CA 분비작용은 현저한 감소를 나타냈었다. Pentazocine $(1.75{\times}10^{-4}\;M)$을 20분간 관류시킨 후에 ACh $(5.32{\times}10^{-3}\;M)$과 DMPP $(10^{-4}\;M)$에 의한 CA 분비작용이 의의 있게 감약되었다. 이상과 같은 연구결과를 종합하면, pentazocine은 횐쥐 적출 관류부신에 투여시 현저한 CA 분비작용을 일으키고 있는 칼슘의존성 exocytotic mechanism에 의한 것으로 생각되며, 이러한 pentazocine의 CA 분비작용은 부신 chromaffin cell에 있는 opioid 수용체의 활성화를 통하여 나타나며, 또한 부신의 nicotine 수용체의 흥분작용과도 관련성이 있는 것으로 사료된다.

• International Journal of Oral Biology
• /
• 제37권1호
• /
• pp.1-7
• /
• 2012

Opioid receptors have been pharmacologically classified as ${\mu}$, ${\delta}$, ${\kappa}$ and ${\varepsilon}$. We have recently reported that the antinociceptive effect of morphine (a ${\mu}$-opioid receptor agonist), but not that of ${\beta}$-endorphin (a novel ${\mu}/{\varepsilon}$-opioid receptor agonist), is attenuated by whole body irradiation (WBI). It is unclear at present whether WBI has differential effects on the antinociceptive effects of ${\mu}-$, ${\delta}-$, ${\kappa}-$ and ${\varepsilon}$-opioid receptor agonists. In our current experiments, male ICR mice were exposed to WBI (5Gy) from a $^{60}Co$ gamma-source and the antinociceptive effects of opioid receptor agonists were assessed two hours later using the hot water ($52^{\circ}C$) tail-immersion test. Morphine and $D-Ala^2$, $N-Me-Phe^4$, Gly-olenkephalin (DAMGO), [$D-Pen^2-D-Pen^5$] enkephalin (DPDPE), trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide (U50,488H), and ${\beta}$-endorphin were tested as agonists for ${\mu}$, ${\delta}$, ${\kappa}$, and ${\varepsilon}$-opioid receptors, respectively. WBI significantly attenuated the antinociceptive effects of morphine and DAMGO, but increased those of ${\beta}$-endorphin. The antinociceptive effects of DPDPE and U50,488H were not affected by WBI. In addition, to more preciously understand the differential effects of WBI on ${\mu}-$ and ${\varepsilon}$-opioid receptor agonists, we assessed pretreatment effects of ${\beta}$-funaltrexamine (${\beta}$-FNA, a ${\mu}$-opioid receptor antagonist) or ${\beta}$-$endorphin_{1-27}$ (${\beta}$-$EP_{1-27}$, an ${\varepsilon}$-opioid receptor antagonist), and found that pretreatment with ${\beta}$-FNA significantly attenuated the antinociceptive effects of morphine and ${\beta}$-endorphin by WBI. ${\beta}$-$EP_{1-27}$ significantly reversed the attenuation of morphine by WBI and significantly attenuated the increased effects of ${\beta}$-endorphin by WBI. The results demonstrate differential sensitivities of opioid receptors to WBI, especially for ${\mu}-$ and ${\varepsilon}$-opioid receptors.

• Journal of Pharmaceutical Investigation
• /
• 제22권3호
• /
• pp.173-183
• /
• 1992

To study the feasibility of transmucosal delivery of $[D-ala^2]-methionine$ enkephalinamide (YAGFM), its enzymatic degradation and stabilization in various rabbit mucosal extracts were investigated by HPLC method. The degradation of YAGFM was observed to follow the first-order kinetics and the half-lives of YAGFM in the nasal, rectal and vaginal mucosal extracts were found to be 25.7, 3.0 and 7.8 hr, respectively. However, there was no significant difference in degradation rates of YAGFM between the mucosal and serosal extracts obtained from the same mucosal membrane. This finding suggests that even a synthetic enkephalin analog, which is designed to be resistent to aminopeptidases, needs to be fully protected from the enzymatic degradation in mucosal sites for the delivery of the analog through mucosal routes. To inhibit the degradation of YAGFM in various mucosal extracts, effects of enzyme inhibitors such as bestatin (BS), amastatin (AM), thiorphan (TP), thimerosal (TM) and EDTA, alone or in combination, and modified cyclodextrins were observed by assaying YAGFM staying intact during 24 hr-incubation at $37^{\circ}C$. It was found from the results that mixed inhibitors such as TM (0.5 mM)/EDTA (5 mM) or AM $(50{\mu}M)/TM$ (0.5 mM)/EDTA (5 mM) provided very useful means for the stabilization in various mucosal extracts. The latter was found to protect YAGFM from the degradation in the nasal, rectal, and vaginal mucosal extracts by 90.9, 90.4 and 91.3%, respectively, after 24 hr-incubation, suggesting almost complete inhibition of YAGFM-degrading enzymes present in the incubation mixture. However, BS $(50{\mu}M)$, AM 50 $(50{\mu}M)$ or TP$(50{\mu}M)$ alone did not reveal sufficient inhibition except TM (0.5 mM) or EDTA (5 mM). The adddition of $2-hydroxylpropyl-{\beta}-cyclodextrin$(10%) to the nasal mucosal extract, and $dimethyl-{\beta}-cyclodextrin$(10%) to the rectal and vaginal mucosal extracts reduced the first-order rate constants for the degradation of YAGFM by 5.8, 17.3 and 8.9 times, respectively, compared to those with no additive.